NBD-11021
NBD-11021 is a HIV-1 entry antagonist and CD4 antagonist. NBD-11021 binds to the Phe43 cavity of HIV-1 gp120 and competitively blocks the gp120-CD4 interaction. NBD-11021 exhibits broad-spectrum inhibitory activity against 56 HIV-1 Env pseudoviruses of different subtypes, with an IC50 of 0.6-5.3 μM. NBD-11021 inhibits CCR5- and CXCR4-tropic HIV-1, primary HIV-1, drug-resistant HIV-1, HIV-1 Env-mediated cell fusion and intercellular viral transmission. NBD-11021 can be used in studies related to HIV-1 gp120, viral entry and HIV infection.
商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。
- CAS 番号: 1427304-84-4
- 分子式: C22H25ClN4O2S
- 分子量:444.98
-
保管条件:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
生物活性
-
化学情報
- 純度とドキュメンテーション
- 参考文献
-
Help & FAQs
生物活性
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| MT2 | CC50 |
24.8 μM
Compound: 89
|
Cytotoxicity against human MT2 cells incubated for 4 days by XTT assay
Cytotoxicity against human MT2 cells incubated for 4 days by XTT assay
|
[PMID: 28266845] |
| TZM | CC50 |
23.6 μM
Compound: 89
|
Cytotoxicity against human TZM-bl cells incubated for 3 days by XTT assay
Cytotoxicity against human TZM-bl cells incubated for 3 days by XTT assay
|
[PMID: 28266845] |
NBD-11021 (compound 89) inhibits CCR5-tropic HIV-1ADA and CXCR4-tropic HIV-1HXB2 infection in U87-CD4-CCR5 and U87-CD4-CXCR4 cells, respectively, with IC50 values of 1.7 μM and 2.4 μM[3].
NBD-11021 exhibits broad-spectrum inhibitory activity against 56 HIV-1 Env pseudoviruses covering multiple clades, with an IC50 range of 0.6-5.3 μM and a mean IC50 of 2.38 μM[3].
NBD-11021 inhibits cell-to-cell transmission of CXCR4-tropic and CCR5-tropic HIV-1 in a co-culture system of GHOST X4/R5 target cells and chronically infected effector cells[3].
NBD-11021 inhibits single-cycle infection of HIV-1HXB2 in TZM-bl cells and multi-cycle infection of HIV-1IIIB in MT-2 cells, with IC50 values of 2.2 μM and 0.85 μM, respectively[1].
NBD-11021 (pretreated for 1 h followed by 24 h of co-culture) inhibits HIV-1 Env-mediated cell fusion between MAGI-CCR5 and HL2/3 cells, with an IC50 of 6.1 μM[1].
NBD-11021 inhibits laboratory-adapted, primary, and drug-resistant HIV-1 strains, including AZT-resistant strains, protease inhibitor-resistant strains, and gp41 fusion inhibitor-resistant strains, in MT-2 cells or PBMC[3].
NBD-11021 (pretreated for 1 h; co-cultured for 24 h) inhibits HIV-1 Env-mediated cell fusion between MAGI-CCR5 and HL2/3 cells, with an IC50 of 9.8 μM[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
化学情報
-
CAS 番号 1427304-84-4
-
分子量 444.98
-
分子式 C22H25ClN4O2S
-
SMILES
O=C(C1=CC=C(C2=CC=C(Cl)C=C2)N1)NC(C3=NC(C)=C(CO)S3)C4NCCCC4
-
輸送条件
Room temperature in continental US; may vary elsewhere.
-
保管条件
Please store the product under the recommended conditions in the Certificate of Analysis.
純度とドキュメンテーション
参考文献
[1]. Curreli F, et al. Synthesis, Antiviral Potency, in Vitro ADMET, and X-ray Structure of Potent CD4 Mimics as Entry Inhibitors That Target the Phe43 Cavity of HIV-1 gp120. Journal of medicinal chemistry. 2017 Apr 13;60(7):3124-3153. [Content Brief]
[3]. Curreli F, et al. Structure-Based Design of a Small Molecule CD4-Antagonist with Broad Spectrum Anti-HIV-1 Activity. Journal of medicinal chemistry. 2015 Sep 10;58(17):6909-6927. [Content Brief]
[4]. Curreli F, et al. Preclinical Optimization of gp120 Entry Antagonists as anti-HIV-1 Agents with Improved Cytotoxicity and ADME Properties through Rational Design, Synthesis, and Antiviral Evaluation. Journal of medicinal chemistry. 2020 Feb 27;63(4):1724-1749. [Content Brief]
Calculators
濃度 (開始) × 体積 (開始) = 濃度 (終了) × 体積 (終了)
NBD-11021 関連分類
HY-117855 関連分類
Powered by Bioz